Koers Hansa Biopharma AB Mexican S.E.
Aandelen
HNSA N
SE0002148817
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
160,8 MXN | -.--% | -.--% | -.--% |
Omzet 2024 * | 239 mln. 22,71 mln. 418 mln. 21,02 mln. | Omzet 2025 * | 343 mln. 32,53 mln. 599 mln. 30,11 mln. | Marktkapitalisatie | 3,23 mld. 307 mln. 5,65 mld. 284 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -735 mln. -69,78 mln. -1,29 mld. -64,59 mln. | Nettowinst (verlies) 2025 * | -712 mln. -67,59 mln. -1,25 mld. -62,57 mln. | EV/omzet 2024 * | 15,5 x |
Nettoschuld 2024 * | 474 mln. 45 mln. 829 mln. 41,65 mln. | Nettoschuld 2025 * | 733 mln. 69,62 mln. 1,28 mld. 64,45 mln. | EV/omzet 2025 * | 11,6 x |
K/w-verhouding 2024 * |
-4,44
x | K/w-verhouding 2025 * |
-5,27
x | Werknemers | 166 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,64% |
Recentste transcriptie over Hansa Biopharma AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 20-03-18 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/12 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 29-05-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 73 | 29-05-18 | |
Peter Nicklin
CHM | Chairman | 61 | 30-06-22 |
Mats Blom
BRD | Director/Board Member | 59 | 22-05-19 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+51,85% | 57,87 mld. | |
+41,42% | 40,25 mld. | |
-5,25% | 39,94 mld. | |
-5,16% | 28,54 mld. | |
+12,79% | 26,4 mld. | |
-20,18% | 19,33 mld. | |
+30,88% | 12,4 mld. | |
+0,61% | 12,23 mld. | |
+25,06% | 12,2 mld. |
- Beurs
- Aandelen
- Koers HNSA
- Koers HNSA N